Dermata Therapeutics, Inc.

DRMA • Biotechnology

$1.21

▼ -0.02 (-1.63%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$4.87M

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0Healthy liquidity · 4.79Weak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 20, 2026, 12:24 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$1.21

Change-1.63%

Shares Out4.02M

Market Cap$4.87M

Enterprise Value$454.03K

52W Range0.95 - 6.22

Beta0.66

P/E-0.58

P/B1.40

P/FCF-0.60

EV/EBITDA-0.05

EV/FCF-0.06

Price$1.21

Change-1.63%

Shares Out4.02M

Market Cap$4.87M

Enterprise Value$454.03K

52W Range0.95 - 6.22

Beta0.66

P/E-0.58

P/B1.40

P/FCF-0.60

EV/EBITDA-0.05

EV/FCF-0.06

Earnings Yield-171.95%

FCF Yield-167.36%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.00

Current Ratio4.79

Quick Ratio4.79

Target$6.00

Target Upside395.87%

Target Median$6.00

Target Range6.00 - 6.00

Volume141.81K

Avg Volume73.51K

EPS Surprise0.05

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

70/100

Growth Potential

Revenue and expansion

50/100

Price Attractiveness

Cheap or expensive today

95/100

Why this score▼

Manageable debt level · 0Healthy liquidity · 4.79Weak profitability

Analyst view

Analyst sentiment and price target

DRMA

Analyst sentiment

Based on 1 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Price Target

2026-08-20

Low

$6.00

Mean

$6.00

Median

$6.00

High

$6.00

Company Overview

IPO: 8/13/2021

Industry: Biotechnology

P/B i: 1.40

Debt / Equity i: 0.00

Operating Margin: 0.00%

Net Margin: 0.00%

ROE i: -

ROIC: -

Financial Health

Score14 / 20

Debt / Equity: 0.00

Current Ratio: 4.79

Quick Ratio: 4.79

Status: Good

Insider Transactions

Recent executive and insider activity

Van Hoose Kyri K.

Transaction: 08/16/2026

BUY

Change

+102,040

Price

$1.47

Filing

08/18/2026

Type

BUY

Van Hoose Kyri K.

Transaction: 08/16/2026

BUY

Change

+102,040

Price

$1.47

Filing

08/18/2026

Type

BUY

Van Hoose Kyri K.

Transaction: 08/16/2026

BUY

Change

+102,040

Price

Not reported

Filing

08/18/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
Van Hoose Kyri K.	BUY	+102,040	$1.47	08/16/2026	08/18/2026
Van Hoose Kyri K.	BUY	+102,040	$1.47	08/16/2026	08/18/2026
Van Hoose Kyri K.	BUY	+102,040	Not reported	08/16/2026	08/18/2026
PROEHL GERALD T	BUY	+170,068	Not reported	08/16/2026	08/18/2026
PROEHL GERALD T	BUY	+170,068	$1.47	08/16/2026	08/18/2026
PROEHL GERALD T	BUY	+170,068	$1.47	08/16/2026	08/18/2026
PROEHL GERALD T	BUY	+1,360,544	$0.00	08/16/2026	08/18/2026
Scott Kathleen D.	SELL	-11	$1.19	06/16/2026	06/16/2026
Bedoya-Toro Munera Maria E	BUY	+1,000	$1.27	02/17/2026	03/17/2026
FISHER MARY	BUY	+2,500	$2.18	01/02/2026	01/06/2026
Bradrick Brittany	BUY	+2,500	$2.18	01/02/2026	01/06/2026
Mento Steven J	BUY	+2,500	$2.18	01/02/2026	01/06/2026
Van Hoose Kyri K.	BUY	+18,000	$2.18	01/02/2026	01/06/2026
Sandler Andrew Seth	BUY	+2,500	$2.18	01/02/2026	01/06/2026
Nardo Christopher J.	BUY	+18,000	$2.18	01/02/2026	01/06/2026
Scott Kathleen D.	BUY	+2,500	$2.18	01/02/2026	01/06/2026
Bedoya-Toro Munera Maria E	BUY	+9,000	$2.18	01/02/2026	01/06/2026
WIERENGA WENDELL	BUY	+2,500	$2.18	01/02/2026	01/06/2026
HALE DAVID F	BUY	+2,500	$2.18	01/02/2026	01/06/2026
PROEHL GERALD T	BUY	+37,500	$2.18	01/02/2026	01/06/2026

About the Company

Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.

Source - link

Peers

ARTL ATXI CARM ELAB GTBP LIPO PBM REVB VRAX WINT

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment

- Tome Foundational Treatment, powered by Bioneedle™, is now available for purchase at www.tomeskincare.com - - Once-weekly Foundational Treatment is designed to renew the appearance of skin and improve tone and texture over time - - Consumers can purchase a one-month kit or subscribe for convenient recurring delivery - SAN DIEGO, CA / ACCESS Newswire / August 25, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced the official commercial launch of the Tome Foundational Treatment, the first product available for purchase under the Company's Tome skincare brand. The Foundational Treatment is now available for immediate purchase at www.tomeskincare.com, either as a one-time purchase or through a monthly subscription at a discounted price.

Accesswire

Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch

- Preorders can be made by visiting www.tomeskincare.com - - Dermata is ready to begin shipping orders on the expected launch date of August 25, 2026 - - Tome Foundational Treatment is a once-weekly topical mask for skin renewal - SAN DIEGO, CA / ACCESS Newswire / August 21, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced that Tome Foundational Treatment, the Company's first direct-to-consumer skincare product, is now open to preorders. The Tome Foundational Treatment is expected to start shipping on August 25, 2026.

Accesswire

Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$3.4 million upfront with up to approximately $6.7 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESS Newswire / August 17, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,293,608 shares of common stock (or pre-funded warrants in lieu thereof), series E warrants to purchase up to 2,293,608 shares of common stock and short-term series F warrants to purchase up to 2,293,608 shares of common stock at a purchase price of $1.46 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under the rules of the Nasdaq Stock Market. The series E warrants and the series F warrants will have an exercise price of $1.46 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants.

Accesswire

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

- Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026 - - Dermata recently attended Be+Well Beauty and Wellness Show in Las Vegas, NV to announce the Tome brand - SAN DIEGO, CA / ACCESS Newswire / August 11, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the second quarter ended June 30, 2026. "Over the past year, we have transformed Dermata through a strategic pivot to become a commercial-stage, direct-to-consumer skincare company," commented Gerry Proehl, Dermata's Chairman, President, and CEO.

Accesswire

Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment

- A new chapter in skincare has arrived - - This will be Dermata's first commercial product launch, planned for August 25, 2026 - - Join the waitlist at tomeskincare.com - SAN DIEGO, CA / ACCESS Newswire / August 5, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced that Tome Foundational Treatment, the Company's first direct-to-consumer skincare product, is planned to launch on August 25, 2026, with those on the waitlist getting early access to preorder. The launch of the Foundational Treatment represents a significant milestone in Dermata's strategic evolution toward becoming a consumer-focused, revenue-generating, skincare company.

Accesswire

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-13	-0.53	-0.48	0.05
2026-03-26	-1.54	-1.52	0.02
2025-11-14	-1.59	-1.65	-0.06
2025-08-13	-2.9	-1.66	1.24
2025-05-14	-0.45	-4.5	-4.05
2025-03-17	-1.5	-3.15	-1.65
2024-11-13	-2.64	-2.04	0.6
2024-08-07	-3.79	-4.18	-0.39
2024-05-15	-5.4	-7.05	-1.65
2024-03-21	-0.78	-3.15	-2.37
2023-11-09	-0.63	-8.1	-7.47
2023-08-10	-0.92	-9.45	-8.53